๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Sickle Cells Patients

A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke NCT05953584Phase 29 sites๐Ÿ“ Raipur๐Ÿ“ Delhi๐Ÿ“ Gujarat Forma Therapeutics, Inc. ยท Tests: Etavopivat, Hydroxyurea A Long-term Follow-up Study in Patients Who Received BEAM-101 NCT07373639n/a17 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Jacksonville Beam Therapeutics Inc. ยท Tests: Long-Term Follow-up Study of patients who received BEAM-101 Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype NCT07282210Phase 24 sites๐Ÿ“ Toronto๐Ÿ“ Toronto๐Ÿ“ Montreal Biossil Inc. ยท Tests: Senicapoc, Placebo Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC NCT04528355n/a1 site๐Ÿ“ Pittsburgh Paul Szabolcs ยท Tests: data collection A Real-World Registry of Chronic Wounds and Ulcers NCT02280733n/a1 site๐Ÿ“ The Woodlands U.S. Wound Registry ยท Tests: Usual care Study of Vitamin B12 Metabolism in Children With Sickle Cell Disease Exposed to MEOPA NCT06581900n/a1 site๐Ÿ“ Reims CHU de Reims ยท Tests: Vitamin B12 T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias NCT03653338Phase 1, Phase 21 site๐Ÿ“ Pittsburgh Paul Szabolcs ยท Tests: CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises NCT06184126NA1 site๐Ÿ“ Baltimore University of Maryland, Baltimore ยท Tests: Virtual Reality Headset and Hand-Held Controllers, Blindfolding and Noise Cancelling Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients NCT07000747n/a1 site๐Ÿ“ Pointe-ร -Pitre Centre Hospitalier Universitaire de la Guadeloupe CS-206 in Patients With Sickle Cell Disease NCT06565026EARLY Phase 11 site๐Ÿ“ Nanning CorrectSequence Therapeutics Co., Ltd ยท Tests: CS-206 A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease NCT06546670Phase 1, Phase 213 sites๐Ÿ“ Birmingham๐Ÿ“ Miami๐Ÿ“ Boston Novartis Pharmaceuticals ยท Tests: ITU512, Placebo Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease NCT07252050Phase 1, Phase 24 sites๐Ÿ“ Aurora๐Ÿ“ Atlanta๐Ÿ“ New Orleans Arkansas Children's Hospital Research Institute ยท Tests: Ruxolitinib A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD NCT04201210Phase 29 sites๐Ÿ“ Vienna๐Ÿ“ Aachen๐Ÿ“ Berlin University of Regensburg ยท Tests: TCRฮฑ/ฮฒ+ and CD19+ depleted haploidentical stem cell transplantation, Matched sibling donor transplantation Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease NCT06941389n/a37 sites๐Ÿ“ Birmingham๐Ÿ“ Birmingham๐Ÿ“ Wilmington University of Rochester Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease NCT03685721n/a1 site๐Ÿ“ Bethesda National Heart, Lung, and Blood Institute (NHLBI) Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia NCT06761560Phase 2, Phase 31 site๐Ÿ“ Montreal Yves Pastore ยท Tests: Pharmacokinetic based dosage change, Pharmacokinetic dosing Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease NCT06635902Phase 21 site๐Ÿ“ Washington D.C. Suvankar Majumdar ยท Tests: L-citrulline, Placebo, L-citrulline Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease NCT07090668NA1 site๐Ÿ“ Atlanta Emory University ยท Tests: tAN device Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study NCT04657822Phase 431 sites๐Ÿ“ Birmingham๐Ÿ“ Washington D.C.๐Ÿ“ Augusta Novartis Pharmaceuticals ยท Tests: Crizanlizumab Long-term Endurance Training in Sickle Cell Disease Patients: Impact on Clinical Profile, Physical Fitness, and Quality of Life. NCT06823219NA1 site๐Ÿ“ Crรฉteil Assistance Publique - Hรดpitaux de Paris ยท Tests: endurance training program Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease NCT02675959Phase 24 sites๐Ÿ“ Los Angeles๐Ÿ“ Gainesville๐Ÿ“ Valhalla New York Medical College ยท Tests: Defibrotide Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease NCT06944067n/a1 site๐Ÿ“ Bethesda National Human Genome Research Institute (NHGRI) Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease NCT06818266Phase 31 site๐Ÿ“ Paris Assistance Publique - Hรดpitaux de Paris ยท Tests: Tocilizumab (RoActemraยฎ, 20 mg/mL)., Placebo (NaCl 0.9%) Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody NCT06358638Phase 21 site๐Ÿ“ Washington D.C. Children's National Research Institute ยท Tests: Daratumumab, Alemtuzumab, Sirolimus, Total Body Irradiation Pediatric -Adult Care Transition Program of Patients With Sickle Cell Disease NCT03786549NA8 sites๐Ÿ“ Fort-de-France-La Martinique๐Ÿ“ Crรฉteil๐Ÿ“ Crรฉteil Hospices Civils de Lyon ยท Tests: pediatric-adult care transition program High-flow Oxygen for Vaso-occlusive Pain Crisis NCT03976180NA1 site๐Ÿ“ Crรฉteil Assistance Publique - Hรดpitaux de Paris ยท Tests: Stadard low-flow oxygen, HFNO with low FiO2 (21%-30%), HFNO with intermediate FiO2 (50%), HFNO with high FiO2 (100%) Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease NCT06919224NA4 sites๐Ÿ“ Chicago๐Ÿ“ St Louis๐Ÿ“ Columbus Ohio State University ยท Tests: mHealth app + booklets Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care NCT07246265NA6 sites๐Ÿ“ Tours๐Ÿ“ Crรฉteil๐Ÿ“ Le Mans University Hospital, Tours ยท Tests: Injection of iohexol for glomerular filtration rate (GFR) measurement Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease NCT06385886n/a9 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Oakland RTI International ยท Tests: Linkage Coordinator Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain NCT06773715NA1 site๐Ÿ“ New Orleans Louisiana State University Health Sciences Center in New Orโ€ฆ ยท Tests: KindVR Aqua Program
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy